Clinical Trial Update: Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating capecitabine combined with an aromatase inhibitor versus aromatase inhibitors alone in HR-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Capecitabine (capecitabine)

Snippet

Sponsor: Ain Shams University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN